EntroGen, Inc

EntroGen, Inc. is a molecular diagnostics company specializing in oncology and personalized medicine solutions. The company develops and manufactures FDA-approved and research-use-only (RUO) PCR-based assays for cancer biomarker detection, companion diagnostics, and minimal residual disease (MRD) monitoring. Core product portfolio includes the CRCdx® RAS Mutation Detection Kit (FDA-approved companion diagnostic for KRAS and NRAS mutations in colorectal cancer), NPM1 One-Step MRD Kit for acute myeloid leukemia detection, DPYD Genotyping Kit for pharmacogenomic assessment, and Microsatellite Instability (MSI) Detection Kit. EntroGen manufactures the Benchbot® 4800 laboratory automation platform designed to streamline workflow from sample preparation to PCR plate setup in four steps. The company offers three integrated product lines: automation equipment, molecular reagents/assays, and analysis software. All products are manufactured to ISO 13485 quality standards. EntroGen serves clinical laboratories, hospital pathology departments, and oncology centers globally, supporting treatment decision-making through molecular testing. The company participates in industry conferences including the World Clinical Biomarkers & Companion Diagnostics Summit, indicating active engagement in the molecular diagnostics and precision oncology markets.